200 related articles for article (PubMed ID: 10390205)
21. Mechanisms of action and resistance of older and newer fluoroquinolones.
Hooper DC
Clin Infect Dis; 2000 Aug; 31 Suppl 2():S24-8. PubMed ID: 10984324
[TBL] [Abstract][Full Text] [Related]
22. Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae.
Onodera Y; Uchida Y; Tanaka M; Sato K
J Antimicrob Chemother; 1999 Oct; 44(4):533-6. PubMed ID: 10588315
[TBL] [Abstract][Full Text] [Related]
23. Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases.
Takei M; Fukuda H; Yasue T; Hosaka M; Oomori Y
Antimicrob Agents Chemother; 1998 Oct; 42(10):2678-81. PubMed ID: 9756776
[TBL] [Abstract][Full Text] [Related]
24. Topoisomerase mutations in trovafloxacin-resistant Staphylococcus aureus.
Fitzgibbon JE; John JF; Delucia JL; Dubin DT
Antimicrob Agents Chemother; 1998 Aug; 42(8):2122-4. PubMed ID: 9687420
[TBL] [Abstract][Full Text] [Related]
25. Quinolone resistance in Staphylococci: activities of new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates.
Roychoudhury S; Catrenich CE; McIntosh EJ; McKeever HD; Makin KM; Koenigs PM; Ledoussal B
Antimicrob Agents Chemother; 2001 Apr; 45(4):1115-20. PubMed ID: 11257024
[TBL] [Abstract][Full Text] [Related]
26. A 2.8 Å Structure of Zoliflodacin in a DNA Cleavage Complex with
Morgan H; Lipka-Lloyd M; Warren AJ; Hughes N; Holmes J; Burton NP; Mahenthiralingam E; Bax BD
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675148
[TBL] [Abstract][Full Text] [Related]
27. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
Cheng J; Thanassi JA; Thoma CL; Bradbury BJ; Deshpande M; Pucci MJ
Antimicrob Agents Chemother; 2007 Jul; 51(7):2445-53. PubMed ID: 17502409
[TBL] [Abstract][Full Text] [Related]
28. Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones.
Pestova E; Beyer R; Cianciotto NP; Noskin GA; Peterson LR
Antimicrob Agents Chemother; 1999 Aug; 43(8):2000-4. PubMed ID: 10428926
[TBL] [Abstract][Full Text] [Related]
29. DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage.
Chen CR; Malik M; Snyder M; Drlica K
J Mol Biol; 1996 May; 258(4):627-37. PubMed ID: 8636997
[TBL] [Abstract][Full Text] [Related]
30. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro.
Gootz TD; Zaniewski R; Haskell S; Schmieder B; Tankovic J; Girard D; Courvalin P; Polzer RJ
Antimicrob Agents Chemother; 1996 Dec; 40(12):2691-7. PubMed ID: 9124824
[TBL] [Abstract][Full Text] [Related]
31. Relationship between mutations in the DNA gyrase and topoisomerase IV genes and nadifloxacin resistance in clinically isolated quinolone-resistant Staphylococcus aureus.
Oizumi N; Kawabata S; Hirao M; Watanabe K; Okuno S; Fujiwara T; Kikuchi M
J Infect Chemother; 2001 Sep; 7(3):191-4. PubMed ID: 11810583
[TBL] [Abstract][Full Text] [Related]
32. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.
Pan XS; Fisher LM
Antimicrob Agents Chemother; 1997 Feb; 41(2):471-4. PubMed ID: 9021211
[TBL] [Abstract][Full Text] [Related]
33. Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerases purified as recombinant proteins.
Morrissey I; George J
Antimicrob Agents Chemother; 1999 Nov; 43(11):2579-85. PubMed ID: 10543732
[TBL] [Abstract][Full Text] [Related]
34. Norfloxacin-induced DNA cleavage occurs at the dif resolvase locus in Escherichia coli and is the result of interaction with topoisomerase IV.
Hojgaard A; Szerlong H; Tabor C; Kuempel P
Mol Microbiol; 1999 Sep; 33(5):1027-36. PubMed ID: 10476036
[TBL] [Abstract][Full Text] [Related]
35. Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance.
Hooper DC
Clin Infect Dis; 1998 Aug; 27 Suppl 1():S54-63. PubMed ID: 9710672
[TBL] [Abstract][Full Text] [Related]
36. Cloning, expression, and enzymatic characterization of Pseudomonas aeruginosa topoisomerase IV.
Akasaka T; Onodera Y; Tanaka M; Sato K
Antimicrob Agents Chemother; 1999 Mar; 43(3):530-6. PubMed ID: 10049263
[TBL] [Abstract][Full Text] [Related]
37. Dual inhibition of Staphylococcus aureus DNA gyrase and topoisomerase IV activity by phenylalanine-derived (Z)-5-arylmethylidene rhodanines.
Werner MM; Patel BA; Talele TT; Ashby CR; Li Z; Zauhar RJ
Bioorg Med Chem; 2015 Sep; 23(18):6125-37. PubMed ID: 26320664
[TBL] [Abstract][Full Text] [Related]
38. Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates.
Schmitz FJ; Fluit AC; Brisse S; Verhoef J; Köhrer K; Milatovic D
FEMS Immunol Med Microbiol; 1999 Dec; 26(3-4):281-7. PubMed ID: 10575140
[TBL] [Abstract][Full Text] [Related]
39. The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase.
Bhagwat SS; Mundkur LA; Gupte SV; Patel MV; Khorakiwala HF
Antimicrob Agents Chemother; 2006 Nov; 50(11):3568-79. PubMed ID: 16940059
[TBL] [Abstract][Full Text] [Related]
40. DNA Topoisomerase Inhibitors: Trapping a DNA-Cleaving Machine in Motion.
Bax BD; Murshudov G; Maxwell A; Germe T
J Mol Biol; 2019 Aug; 431(18):3427-3449. PubMed ID: 31301408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
